Top

Journal of General Internal Medicine

Published in:

01-09-2020 | Septicemia | Review Paper

Antithrombotic Therapies in COVID-19 Disease: a Systematic Review

Authors: Edward Maldonado, MD, Derrick Tao, MD, Katherine Mackey, MD, MPP

Published in: Journal of General Internal Medicine | Issue 9/2020

Abstract

Background

Infection with coronavirus SARS-CoV-2, causing COVID-19 disease, leads to inflammation and a prothrombotic state.

Objective

This rapid systematic review aims to synthesize evidence on thromboembolism incidence and outcomes with antithrombotic therapies in COVID-19.

Data Sources

We searched MEDLINE (Ovid), Cochrane Rapid Reviews, PROSPERO, and the WHO COVID-19 Database from January 1, 2003, to April 22, 2020, for studies meeting pre-specified inclusion criteria.

Study Selection, Data Extraction, and Synthesis

One investigator identified articles for inclusion, abstracted data, and performed quality assessment, with second reviewer checking.

Results

Incidence of thromboembolism among hospitalized patients with COVID-19 ranged from 25 to 53% in 4 retrospective series. We identified 3 studies (1 retrospective cohort study, 1 prospective uncontrolled observational study, and 1 case series) examining outcomes among COVID-19 patients who received antithrombotic therapies. These studies all included different interventions (thromboprophylaxis with unfractionated heparin (UFH) or low molecular-weight heparin (LMWH); an intensive thromboprophylaxis protocol with LMWH, antithrombin, and clopidogrel; and salvage therapy with tissue plasminogen activator and heparin). These studies are overall poor quality due to methodological limitations including unclear patient selection protocols, lack of reporting or adjustment for patient baseline characteristics, inadequate duration of follow-up, and partial reporting of outcomes.

Conclusions

New evidence on thromboembolism in COVID-19 does not warrant a change in current guidance on thromboprophylaxis among hospitalized patients. Prospective trials of antithrombotic treatment strategies among patients with COVID-19 are urgently needed.

Han H, Yang L, Liu R, et al. Prominent changes in blood coagulation of patients with SARS-CoV-2 infection. [published online ahead of print, 2020 Mar 16]. Clin Chem Lab Med 2020;/j/cclm.ahead-of-print/cclm-2020-0188/cclm-2020-0188.xml.

Driggin E, Madhavan MV, Bikdeli B, et al. Cardiovascular considerations for patients, health care workers, and health systems during the coronavirus disease 2019 (COVID-19) pandemic. J Am Coll Cardiol. 2020;75(18):2352‐2371.

Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost 2020;18(4):844-847.CrossRef

Hotchkiss RS, Moldawer LL, Opal SM, Reinhart K, Turnbull IR, Vincent J-L. Sepsis and septic shock. Nat Rev Dis Primers 2016;2(1):16045.CrossRef

Ding Y, Wang H, Shen H, et al. The clinical pathology of severe acute respiratory syndrome (SARS): a report from China. J Pathol 2003;200(3):282-289.CrossRef

Yin S, Huang M, Li D, Tang N. Difference of coagulation features between severe pneumonia induced by SARS-CoV2 and non-SARS-CoV2. J Thromb Thrombolysis 2020;1‐4.

Hunt J. Webinar: thrombosis, thromboprophylaxis & coagulopathy in COVID-19 infections. https://academy.isth.org/isth/2020/covid-19/291581/marcel.levi.26.beverley.jane.hunt.webinar.thrombosis.thromboprophylaxis.26.html?f=menu%3D8%2Abrowseby%3D8%2Asortby%3D2%2Alabel%3D19794. Published 2020. Accessed April 13, 2020.

Wang T, Chen R, Liu C, et al. Attention should be paid to venous thromboembolism prophylaxis in the management of COVID-19. Lancet Haematol 2020;7(5):e362‐e363.

Moore HB, C; Moore, C; et al. Is there a role for tissue plasminogen activator (tPA) as a novel treatment for refractory COVID-19 associated acute respiratory distress syndrome (ARDS)? [published online ahead of print, 2020 Mar 20]. J Trauma Acute Care Surg 2020; https://doi.org/10.1097/TA.0000000000002694.

10.

Marietta M, Ageno W, Artoni A, et al. COVID-19 and haemostasis: a position paper from Italian Society on Thrombosis and Haemostasis (SISET). Blood Transfus. 2020;08:08.

11.

Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected. WHO/2019-nCoV/clinical/2020.4. World Health Organization;2020.

12.

Interim clinical guidance for management of patients with confirmed coronavirus disease (COVID-19). https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-guidance-management-patients.html. Published 2020. Updated April 13, 2020. Accessed April 13, 2020.

13.

Matos R; Chung K. DoD COVID-19 practice management guide: clinical management of COVID-19. DoD. https://asprtracie.hhs.gov/technical-resources/resource/7899/dod-covid-19-practice-management-guide-clinical-management-of-covid-19. Published 2020. Updated March 23, 2020. Accessed April 13, 2020.

14.

Thachil J, Tang N, Gando S, et al. ISTH interim guidance on recognition and management of coagulopathy in COVID-19. J Thromb Haemost 2020;18(5):1023‐1026.

15.

Schünemann HJ, Cushman M, Burnett AE, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: prophylaxis for hospitalized and nonhospitalized medical patients. Blood Advan 2018;2(22):3198-3225.CrossRef

16.

Bikdeli B, Madhavan MV, Jimenez D, et al. COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up. J Am Coll Cardiol 2020;15:15.

17.

Tao DL, Bien JY, DeLoughery TG, Shatzel JJ. Extended thromboprophylaxis with direct oral anticoagulants for medical patients: a systematic review and meta-analysis. Blood. 2017;129(5):653-655.CrossRef

18.

Rhodes A, Evans LE, Alhazzani W, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016. Intensive Care Med 2017;43(3):304-377.CrossRef

19.

Bhimraj A, Morgan RL, Shumaker AH, et al. Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19. Infectious Diseases Society of America https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management. Published 2020. Updated April 11, 2020. Accessed April 13, 2020.

20.

Tao D, Maldonado E, and Mackey K. Antithrombotic Therapies for COVID-19 Disease. Washington, DC: Evidence Synthesis Program, Health Services Research and Development Service, Office of Research and Development, Department of Veterans Affairs. VA ESP Project #09-199; 2020.

21.

Berkman ND, Lohr KN, Ansari M, et al. AHRQ methods for effective health care grading the strength of a body of evidence when assessing health care interventions for the effective health Care program of the agency for healthcare research and quality: an update. In: Methods Guide for Effectiveness and Comparative Effectiveness Reviews. Rockville (MD): Agency for Healthcare Research and Quality (US); 2008.

22.

Stewart LA, Clarke M, Rovers M, et al. Preferred Reporting Items for a Systematic Review and Meta-Analysis of individual participant data: the PRISMA-IPD statement. JAMA. 2015;313(16):1657-1665.

23.

Sterne JA, Hernán MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. Bmj. 2016;355:i4919.

24.

Case report guidelines. 2013 CARE Checklist. https://www.care-statement.org/resources/checklist. Published 2013. Updated 2013. Accessed April 19 2020.

25.

Balshem H, Helfand M, Schünemann HJ, et al. GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol 2011;64(4):401-406.

26.

Cui S, Chen S, Li X, Liu S, Wang F. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia [published online ahead of print, 2020 Apr 9]. J Thromb Haemost 2020; https://doi.org/10.1111/jth.14830.

27.

Wang J, Hajizadeh N, Moore EE, et al. Tissue plasminogen activator (tPA) treatment for COVID-19 associated acute respiratory distress syndrome (ARDS): a case series. J Thromb Haemost 2020; https://doi.org/10.1111/jth.14828.

28.

Chen J, Wang, Xiang, Zhang, Shutong, Liu, Bin, Wu, Xiaoqing, Wang, Yanfang, Wang, Xiaoqi, Yang, Ming, Sun, Jianqing, Xie, Yuanliang. Findings of acute pulmonary embolism in COVID-19 patients. Available at SSRN: https://ssrn.com/abstract=3548771. Published 2020. Updated March 1, 2020. Accessed April 13, 2020.

29.

Klok FA, Kruip M, van der Meer NJM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. [published online ahead of print, 2020 Apr 10]. Thromb Res 2020;S0049-3848(20)30120-1.

30.

Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost 2020;18(5):1094-1099.

31.

Marone EM, Rinaldi LF. Upsurge of deep venous thrombosis in patients affected by COVID-19: preliminary data and possible explanations. J Vasc Surg Venous Lymphat Disord 2020;S2213-333X(20)30214-6.

32.

Ranucci M, Ballotta A, Di Dedda U, et al. The procoagulant pattern of patients with COVID-19 acute respiratory distress syndrome. J Thromb Haemost 2020; https://doi.org/10.1111/jth.14854.

33.

Preventing cardiac complication of COVID-19 disease with early acute coronary syndrome therapy: a randomised controlled trial. ClinicalTrials.gov Identifier: NCT04333407. https://clinicaltrials.gov/ct2/show/NCT04333407?term=Preventing+Cardiac+Complication+of+COVID-19+Disease+With+Early+Acute+Coronary+Syndrome+Therapy%3A+A+Randomised+Controlled+Trial.&recrs=ab&draw=2&rank=1. Published 2020. Updated April 9, 2020 Accessed April 24, 2020.

34.

Use of defibrotide to reduce progression of acute respiratory failure rate in patients with COVID-19 pneumonia. ClinicalTrials.gov Identifier: NCT04335201. https://clinicaltrials.gov/ct2/show/NCT04335201?term=Use+of+Defibrotide+to+Reduce+Progression+of+Acute+Respiratory+Failure+Rate+in+Patients+With+COVID-19+Pneumonia&draw=2&rank=1. Published 2020. Updated April 6, 2020. Accessed April 24, 2020

35.

COVID-19 and deep venous thrombosis. ClinicalTrials.gov Identifier: NCT04338932 https://clinicaltrials.gov/ct2/show/NCT04338932?term=NCT04338932&draw=2&rank=1. Published 2020. Updated April 8, 2020. Accessed April 24, 2020.

36.

Pro-thrombotic status in patients with SARS-CoV-2 infection (ATTAC-Co). ClinicalTrials.gov Identifier: NCT04343053 https://clinicaltrials.gov/ct2/show/NCT04343053?term=Pro-thrombotic+Status+in+Patients+with+SARS-CoV-2+Infection+%28ATTAC-Co%29&draw=2&rank=1. Updated April 13. Accessed April 24, 2020.

37.

Preventing COVID-19 complications with low- and high-dose anticoagulation (COVID-HEP). ClinicalTrials.gov Identifier: NCT04345848. https://clinicaltrials.gov/ct2/show/NCT04345848?term=NCT04345848&draw=2&rank=1. Published 2020. Updated April 15, 2020. Accessed April 24, 2020.

38.

Defibrotide as prevention and treatment of respiratory distress and cytokine release syndrome of COVID 19. (DEFACOVID). ClinicalTrials.gov Identifier: NCT04348383 https://clinicaltrials.gov/ct2/show/NCT04348383?term=Defibrotide+as+Prevention+and+Treatment+of+Respiratory+Distress+and+Cytokine+Release+Syndrome+of+Covid+19.+%28DEFACOVID%29&draw=2&rank=1. Published 2020. Updated April 27, 2020. Accessed April 24, 2020.

39.

Austrian CoronaVirus Adaptive Clinical Trial (ACOVACT). ClinicalTrials.gov Identifier: NCT04351724. https://clinicaltrials.gov/ct2/show/NCT04351724?term=Austrian+CoronaVirus+Adaptive+Clinical+Trial+%28ACOVACT%29&draw=2&rank=1. Published 2020. Updated April 24, 2020. Accessed April 24, 2020.

40.

Trial evaluating efficacy and safety of anticoagulation in patients with COVID-19 infection, nested in the Corimmuno-19 Cohort (CORIMMUNO-COAG). ClinicalTrials.gov Identifier: NCT04344756. https://clinicaltrials.gov/ct2/show/NCT04344756?term=NCT04344756&draw=2&rank=1. Published 2020. Updated April 15, 2020. Accessed April 24, 2020, 2020.

41.

Study of alteplase for respiratory failure in SARS-Cov2 (COVID-19) (STARS). ClinicalTrials.gov Identifier: NCT04357730. https://clinicaltrials.gov/ct2/show/NCT04357730?term=Study+of+Alteplase+for+Respiratory+Failure+in+SARS-Cov2+%28COVID-19%29+%28STARS%29&draw=2&rank=1. Published 2020. Updated April 24, 2020. Accessed April 24, 2020.

42.

Nebulised Rt-PA for ARDS due to COVID-19 (PACA). ClinicalTrials.gov Identifier: NCT04356833. https://clinicaltrials.gov/ct2/show/NCT04356833?term=Nebulised+Rt-PA+for+ARDS+Due+to+COVID-19+%28PACA%29&draw=2&rank=1. Published 2020. Updated April 22, 2020. Accessed April 24, 2020.

43.

Analysis of the coagulopathy developed by COVID-19 infected patients: thrombin generation potential in COVID-19 infected patients. ClinicalTrials.gov Identifier: NCT04356950 https://clinicaltrials.gov/ct2/show/NCT04356950?term=Analysis+of+the+Coagulopathy+Developed+by+COVID-19+Infected+Patients%3A+Thrombin+Generation+Potential+in+COVID-19+Infected+Patients&draw=2&rank=1. Published 2020. Updated April 22. Accessed April 24, 2020.

44.

Stephenson K. tPA-COVID-19. Boston Clinical Trials. https://collaborate.hms.harvard.edu/display/covid19/tPA+Study. Published 2020. Updated April 5, 2020. Accessed April 13, 2020.

Title: Antithrombotic Therapies in COVID-19 Disease: a Systematic Review
Authors: Edward Maldonado, MD
Derrick Tao, MD
Katherine Mackey, MD, MPP
Publication date: 01-09-2020
Publisher: Springer International Publishing
Keywords: Septicemia
Septicemia
Tissue Plasminogen Activator
Anticoagulant
Phlebothrombosis
COVID-19
Heparin
Low Molecular Weight Heparin
Published in: Journal of General Internal Medicine / Issue 9/2020
Print ISSN: 0884-8734
Electronic ISSN: 1525-1497
DOI: https://doi.org/10.1007/s11606-020-05906-y

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Antithrombotic Therapies in COVID-19 Disease: a Systematic Review

Abstract

Background

Objective

Data Sources

Study Selection, Data Extraction, and Synthesis

Results

Conclusions

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Objective

Data Sources

Study Selection, Data Extraction, and Synthesis

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 9/2020

Capsule Commentary on Cheah et al., Ethnic Differences in Participation in Medical Check-ups Among the Elderly: Evidence from Malaysia

Risk for Severe COVID-19 Illness Among Health Care Workers Who Work Directly with Patients

Psychological Aspects of the COVID-19 Pandemic

County-Level Association of Social Vulnerability with COVID-19 Cases and Deaths in the USA

Depression and Anxiety Changes Among Sexual and Gender Minority People Coinciding with Onset of COVID-19 Pandemic

Overcoming Inertia: an Exercise in Clinical Reasoning

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page